Sinovac Take-Private Deal Facing Challenges
Executive Summary
Sinovac’s lengthy take-private process could be further delayed by the cloudy outlook for a potential relisting in China due to regulatory uncertainty and a tougher domestic environment, although the Chinese company’s rising competitiveness in the domestic vaccines market should help increase its valuation.
You may also be interested in...
Sinovac Evaluating Competing Take-Private Offers
Beijing-based vaccines group Sinovac Biotech is evaluating two privatization proposals after competing offers from its CEO and an EV17 vaccine rival have emerged in recent days.
Sinovac’s Pioneering EV71 Vaccine Set To Reach First Market
The China FDA has given a production nod to Beijing Sinovac for its EV71 vaccine, which now appears set to be the first product of its type globally to be commercialized. The company expects to launch the vaccine in June and is also actively seeking partners in other Asian countries.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.